Novavax Company Insiders
NVAX Stock | USD 3.97 0.08 2.06% |
Slightly above 90 percent of Novavax's insiders are activelly selling. The analysis of the overall insider sentiment regarding Novavax suggests that a very large number of insiders are panicking. Novavax employs about 1.5 K people. The company is managed by 41 executives with a total tenure of roughly 257 years, averaging almost 6.0 years of service per executive, having 37.63 employees per reported executive.
Stanley Erck CEO CEO and President Director and Member of Fin. Committee |
James Young Chairman Independent Chairman of the Board |
Novavax's Insider Buying Vs Selling
10
Selling | Buying |
Latest Trades
2023-03-10 | Gregory M Glenn | Acquired 1000 @ 6.5 | View | ||
2023-03-06 | Gregory M Glenn | Acquired 3000 @ 7.48 | View | ||
2022-03-31 | James F Young | Disposed 12500 @ 73.58 | View | ||
2022-01-03 | John A Herrmann III | Disposed 5000 @ 140.91 | View | ||
2021-12-20 | John A Herrmann III | Disposed 5000 @ 230 | View | ||
2021-12-15 | Gregory M Glenn | Disposed 1686 @ 174.13 | View | ||
2021-12-07 | Gregory M Glenn | Disposed 8250 @ 170.14 | View | ||
2021-12-01 | John A Herrmann III | Disposed 5000 @ 196.19 | View | ||
2021-11-30 | Gregory M Glenn | Disposed 8942 @ 203.2 | View | ||
2021-11-29 | John A Herrmann III | Disposed 5000 @ 228.72 | View | ||
2021-11-26 | Gregory M Glenn | Disposed 2083 @ 218.07 | View | ||
2021-11-23 | Gregory M Glenn | Disposed 8250 @ 199.5 | View | ||
2021-11-09 | Gregory M Glenn | Disposed 8250 @ 167.53 | View | ||
2021-11-03 | John A Herrmann III | Disposed 5000 @ 200 | View | ||
2021-11-02 | Gregory M Glenn | Disposed 8250 @ 183.82 | View | ||
2021-11-01 | John A Herrmann III | Disposed 5000 @ 163.08 | View | ||
2021-10-29 | Gregory M Glenn | Disposed 680 @ 148.34 | View | ||
2021-10-26 | Gregory M Glenn | Disposed 10334 @ 132.73 | View | ||
2021-10-19 | Gregory M Glenn | Disposed 8250 @ 165.14 | View | ||
2021-10-15 | Gregory M Glenn | Disposed 1183 @ 170 | View |
Monitoring Novavax's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Novavax |
Novavax's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Novavax's future performance. Based on our forecasts, it is anticipated that Novavax will maintain a workforce of slightly above 1540 employees by May 2024.Novavax's latest congressional trading
Congressional trading in companies like Novavax, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Novavax by those in governmental positions are based on the same information available to the general public.
2020-10-13 | Senator Pat Roberts | Acquired Under $15K | Verify |
Novavax Management Team Effectiveness
The company has return on total asset (ROA) of (0.1702) % which means that it has lost $0.1702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.982) %, meaning that it created substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.30 in 2024, whereas Return On Tangible Assets are likely to drop (0.33) in 2024. At this time, Novavax's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 747 M in 2024, whereas Other Current Assets are likely to drop slightly above 191.7 M in 2024.Common Stock Shares Outstanding is likely to rise to about 105.8 M in 2024, despite the fact that Net Loss is likely to grow to (562.5 M).
Novavax Workforce Comparison
Novavax is regarded fourth in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 103,407. Novavax claims roughly 1,543 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.55) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.63) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.63. Novavax Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Novavax insiders, such as employees or executives, is commonly permitted as long as it does not rely on Novavax's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Novavax insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.8824 | 15 | 17 | 1,523,947 | 309,716 |
2023-12-01 | 0.7778 | 7 | 9 | 282,125 | 15,251 |
2023-09-01 | 0.4286 | 3 | 7 | 15,665 | 58,233 |
2023-06-01 | 1.6429 | 23 | 14 | 126,581 | 86,939 |
2023-03-01 | 2.125 | 17 | 8 | 1,041,515 | 29,279 |
2022-12-01 | 0.75 | 6 | 8 | 42,261 | 18,592 |
2022-09-01 | 0.4286 | 3 | 7 | 9,568 | 15,326 |
2022-06-01 | 2.1111 | 19 | 9 | 58,866 | 6,156 |
2022-03-01 | 0.8333 | 10 | 12 | 246,473 | 22,500 |
2021-12-01 | 0.1395 | 36 | 258 | 234,320 | 460,025 |
2021-09-01 | 0.1309 | 36 | 275 | 221,970 | 433,356 |
2021-06-01 | 0.4643 | 65 | 140 | 109,337 | 123,789 |
2021-03-01 | 0.2346 | 42 | 179 | 154,439 | 260,047 |
2020-12-01 | 1.2857 | 18 | 14 | 239,117 | 127,635 |
2020-09-01 | 0.2917 | 42 | 144 | 1,238,246 | 810,018 |
2020-06-01 | 3.6667 | 22 | 6 | 511,780 | 51,921 |
2020-03-01 | 0.625 | 5 | 8 | 8,999 | 10,390 |
2019-12-01 | 6.0 | 6 | 1 | 149,500 | 3,929 |
2019-09-01 | 2.1111 | 19 | 9 | 929,242 | 42,415 |
2017-09-01 | 1.0 | 1 | 1 | 2,057 | 175,000 |
2017-03-01 | 8.0 | 8 | 1 | 529,994 | 100,000 |
2016-03-01 | 3.6 | 18 | 5 | 2,647,773 | 874,778 |
2015-12-01 | 0.3333 | 1 | 3 | 61,886 | 151,717 |
2015-09-01 | 0.9091 | 10 | 11 | 121,463 | 180,758 |
2015-06-01 | 0.0769 | 1 | 13 | 40,000 | 5,050,000 |
2015-03-01 | 5.25 | 21 | 4 | 2,461,235 | 45,600 |
2014-12-01 | 0.5714 | 4 | 7 | 257,500 | 2,291,701 |
2014-09-01 | 4.0 | 8 | 2 | 60,462 | 16,809 |
2014-06-01 | 0.875 | 7 | 8 | 117,000 | 590,000 |
2014-03-01 | 2.0 | 20 | 10 | 2,125,154 | 6,046,000 |
2013-06-01 | 2.3333 | 7 | 3 | 223,000 | 379,000 |
2011-12-01 | 1.5 | 3 | 2 | 204,000 | 250,000 |
2011-09-01 | 1.4 | 7 | 5 | 153,000 | 1,041,376 |
2011-06-01 | 1.0 | 3 | 3 | 1,100,000 | 743,376 |
2010-09-01 | 0.3333 | 1 | 3 | 2,000 | 370,000 |
2010-06-01 | 3.0 | 6 | 2 | 70,000 | 200,000 |
2009-09-01 | 0.1892 | 7 | 37 | 950,000 | 484,696 |
2009-03-01 | 4.0 | 12 | 3 | 552,500 | 47,800 |
2008-09-01 | 4.4 | 22 | 5 | 803,301 | 30,000 |
2007-09-01 | 0.7778 | 7 | 9 | 286,100 | 370,500 |
2006-03-01 | 3.0 | 6 | 2 | 210,000 | 231,555 |
2005-12-01 | 0.5 | 1 | 2 | 10,000 | 20,000 |
2005-09-01 | 1.4286 | 10 | 7 | 1,370,000 | 3,552,839 |
2005-06-01 | 3.0 | 6 | 2 | 105,000 | 20,000 |
2005-03-01 | 0.5 | 1 | 2 | 142,000 | 95,000 |
2004-09-01 | 1.5 | 6 | 4 | 3,799,110 | 900,003 |
2004-03-01 | 6.0 | 6 | 1 | 305,000 | 12,000 |
Novavax Notable Stakeholders
A Novavax stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novavax often face trade-offs trying to please all of them. Novavax's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novavax's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stanley Erck | CEO and President Director and Member of Fin. Committee | Profile | |
John MBA | CEO Director | Profile | |
James Young | Independent Chairman of the Board | Profile | |
MBA BS | President COO | Profile | |
Jody Lichaa | Vice President - Quality Assurance | Profile | |
Brian Webb | Vice President Manufacturing | Profile | |
Jeffrey Stoddard | Vice President - Medical Affairs | Profile | |
Louis Fries | Vice President Chief Medical Officer | Profile | |
John Herrmann | Senior Vice President General Counsel, Corporate Secretary | Profile | |
Nigel Thomas | Vice President - Clinical Operations | Profile | |
Iksung Cho | Vice President - Biostatistics | Profile | |
Susan Hensley | Vice President Regulatory Operations | Profile | |
John Trizzino | Senior Vice President - Commercial Operations | Profile | |
Chris Dunne | Vice President - Finance | Profile | |
Brian Rosen | Senior Vice President - Commercial Strategy | Profile | |
Amy Fix | Senior Vice President - Regulatory Affairs | Profile | |
Mark Twyman | Vice President of Marketing | Profile | |
Russell Wilson | Senior Vice President - Business Development | Profile | |
Bob Darius | Senior Vice President - Quality Operations | Profile | |
Gregory Glenn | Senior Vice President - Research & Development | Profile | |
James Cummings | Vice President - Clinical Development and Translational Medicine | Profile | |
Kathleen Callahan | Vice President Regulatory Affairs, CMC | Profile | |
Barclay Phillips | CFO, Sr. VP and Treasurer | Profile | |
Richard Crowley | Executive COO | Profile | |
Russell JD | Sr. VP of Bus. Devel. | Profile | |
Timothy Hahn | Sr. VP of Global Manufacturing Operations | Profile | |
Michael McManus | Independent Director | Profile | |
Rachel King | Director | Profile | |
Gary Evans | Independent Director | Profile | |
Rajiv Modi | Director | Profile | |
Gail Boudreaux | Director | Profile | |
Richard Douglas | Independent Director | Profile | |
Mark Casey | Chief VP | Profile | |
Silvia MBA | Executive Officer | Profile | |
Erika Trahan | Associate Relations | Profile | |
James CFA | CFO VP | Profile | |
JD Esq | Senior Officer | Profile | |
Ian Watkins | Executive Officer | Profile | |
John III | Chief VP | Profile | |
Biegie Lee | VP Officer | Profile | |
Gale Smith | VP Scientist | Profile |
About Novavax Management Performance
The success or failure of an entity such as Novavax often depends on how effective the management is. Novavax management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novavax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novavax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.32) | (0.33) | |
Return On Capital Employed | (1.88) | (1.79) | |
Return On Assets | (0.29) | (0.31) | |
Return On Equity | 0.76 | 1.30 |
The data published in Novavax's official financial statements usually reflect Novavax's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novavax. For example, before you start analyzing numbers published by Novavax accountants, it's critical to develop an understanding of what Novavax's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Novavax's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novavax's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novavax's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novavax. Please utilize our Beneish M Score to check the likelihood of Novavax's management manipulating its earnings.
Novavax Workforce Analysis
Traditionally, organizations such as Novavax use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novavax within its industry.Novavax Manpower Efficiency
Return on Novavax Manpower
Revenue Per Employee | 637.5K | |
Revenue Per Executive | 24M | |
Net Loss Per Employee | 353.2K | |
Net Loss Per Executive | 13.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.